Related Experiment Video

Updated: Feb 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

PET Imaging of Receptor Tyrosine Kinases in Cancer

Weijun Wei1,2, Dalong Ni2, Emily B Ehlerding3

  • 1Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Molecular Cancer Therapeutics
|August 3, 2018
PubMed

Insights

Positron emission tomography (PET) imaging using radiolabeled antibodies can visualize receptor tyrosine kinases (RTKs) in tumors. This noninvasive diagnostic tool aids in predicting cancer treatment response and developing new drugs.

Area of Science:

  • Oncology
  • Molecular Imaging
  • Radiochemistry

Background:

  • Overexpression and mutations in receptor tyrosine kinases (RTKs) drive tumor growth and invasiveness.
  • Targeted therapies like monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) show success but face resistance.
  • Noninvasive visualization of RTKs is crucial for refining cancer treatment strategies and predicting patient response.

Purpose of the Study:

  • To review the clinical applications of positron emission tomography (PET) imaging for receptor tyrosine kinases (RTKs).
  • To focus on immunoPET probes utilizing radiolabeled antibodies for visualizing tumor RTKs.

Main Methods:

  • Review of existing literature on PET imaging agents targeting RTKs.
  • Emphasis on the use of radiolabeled monoclonal antibodies for immunoPET.
  • Analysis of clinical applications and impact on patient management.

Main Results:

  • Radiolabeled antibody-based PET agents are effective in visualizing tumor RTKs.
  • ImmunoPET is emerging as a valuable tool in clinical decision-making for specific cancer types.
  • These probes facilitate precise response prediction and aid in drug development.

Conclusions:

  • ImmunoPET offers a noninvasive method for detecting and visualizing RTKs in cancer patients.
  • This technology has the potential to significantly improve personalized cancer therapy and drug development.
  • Further clinical application of immunoPET probes is expected to enhance patient outcomes.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.3K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K